CD38 Monoclonal Antibody (HB7), PE-Cyanine7, eBioscience™, Invitrogen™

Description

• The HB7 MAb reacts with the human CD38 molecule, an approximately 45 kDa type II transmembrane protein
• CD38 is an ectoenzyme which catalyses NAD into nicotinic acid adenine dinucleotide phosphate (NAADP) and cyclic ADP-ribose (cADPR), both of which are secondary messengers
• Expression of CD38 is bimodal during B cell development, modulating from high in immature cells to low in intermediate ones and back to high on mature B cells
• Additionally CD38 is found in a variety of tissues and other hematopoietic cells (e.g
• T cells, NK cells and monocytes) and can be used to phenotype leukemias and monitor HIV-1 progression
• The CD34+CD38- population of hematopoietic stems cells is thought to define the most pluripotent cells (e.g
• blast colony forming cells)
• In addition to surface expression, CD38 has recently been found in the nucleus where it may play a role in monitoring calcium levels
• CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells
• CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor
• Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e
• identification of myelomas), and as a marker for activated B and T cells
• CD38 participates in cell adhesion, signal transduction and calcium signaling
• Further, CD38 is expressed at high levels in the pancreas, liver, kidney, malignant lymphoma and neuroblastoma
• Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter's Syndrome.